{"symbol":"LLY","fiscalQuarter":"Q3-2026","reportDate":"2026-10-29","reportTime":"BMO","status":"upcoming","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q3-2026","preBrief":{"companySnapshot":"Eli Lilly and Company (LLY) is a major player in the health care sector, specifically in pharmaceuticals. The company focuses on developing innovative medicines for various conditions, including diabetes and cancer, which are critical areas in today's health landscape.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to increase sales, which is vital for sustaining its market position.","consensus":"N/A"},{"name":"Market Share in Diabetes Treatments","why":"As a leader in diabetes medications, any changes in market share can indicate competitive strength and future revenue potential.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q2 2026, Eli Lilly reported an EPS of $8.38, significantly exceeding expectations by 39.36%. The stock reacted positively, gaining 4.86% the following day.","promises":["Continued focus on expanding its diabetes treatment portfolio.","Commitment to maintaining high levels of research and development investment.","Plans to explore new markets for existing products."]},"wallStreetExpectations":{"summary":"Overall, investors are optimistic about Eli Lilly's upcoming earnings, given its strong performance in previous quarters. However, there are concerns about potential market saturation in key therapeutic areas.","bullCase":"If Eli Lilly continues to outperform expectations, particularly in EPS and revenue growth, it could solidify its position as a market leader and drive further stock appreciation.","bearCase":"On the other hand, if the company fails to meet earnings expectations or shows signs of slowing growth, it could lead to a significant decline in stock price, as seen in past quarters."},"optionsSignal":{"impliedMove":"8.91%","context":"The options market is pricing in an expected move of about 8.91%, indicating that traders anticipate some volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q2-2026","epsSurprise":"+39.36%","reaction":"+4.86%"},{"quarter":"Q1-2026","epsSurprise":"+21.07%","reaction":"+9.80%"},{"quarter":"Q4-2025","epsSurprise":"+7.88%","reaction":"+10.33%"},{"quarter":"Q3-2025","epsSurprise":"+16.59%","reaction":"+3.81%"},{"quarter":"Q2-2025","epsSurprise":"+14.08%","reaction":"-14.14%"}],"pivotalQuestions":[{"question":"What will the EPS be for Q3-2026?","whyItMatters":"Given the strong EPS surprises in previous quarters, this number will be crucial for investor confidence and stock performance."},{"question":"How is Eli Lilly addressing competition in the diabetes treatment market?","whyItMatters":"Understanding the company's strategy in a competitive landscape will be key to assessing future growth potential."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $9.00 or higher would confirm the bull case, indicating strong profitability.","bearTrigger":"An EPS below $7.50 would confirm the bear case, suggesting potential issues in revenue generation.","context":"This quarter's performance is critical as it will set the tone for future growth and market confidence."},"scenarioPlaybook":{"beatAndRaise":"If Eli Lilly beats expectations, history suggests a stock increase of around 3.0%, confirming its strong growth trajectory.","inLineCautious":"If results are in line with expectations, the stock may experience muted movement as investors await further guidance.","miss":"If the company misses expectations, history suggests a potential decline of about 8.97%, raising concerns about its growth prospects."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"12 of 30 (40%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 3.4%, with a raw directional average of -0.4% (modestly negative historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate Eli Lilly's ability to maintain its market share in diabetes treatments, which could lead to stronger-than-expected revenue growth.","supportingPoints":["The company's recent innovations in diabetes care could drive sales beyond current expectations.","Options pricing suggests a significant move, indicating that traders are anticipating more volatility than the consensus reflects."],"riskToConsensus":"If the company reports an EPS significantly above $9.00, it could challenge current market assumptions about growth."},"whatToListenFor":["Any updates on new product launches in the diabetes segment.","Insights into competitive pressures and how the company plans to address them.","Guidance on revenue expectations for the next quarter.","Details on R&D investments and their expected outcomes.","Management's outlook on market conditions and potential challenges."],"metaDescription":"Eli Lilly (LLY) reports Q3 2026 earnings October 29. Analysts expect strong performance following recent successes."}}